Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.
Fiche publication
Date publication
juillet 2018
Journal
Current medical research and opinion
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul
Tous les auteurs :
Herbrecht R, Kuessner D, Pooley N, Posthumus J, Escrig C
Lien Pubmed
Résumé
Voriconazole, amphotericin B (AmB) formulations, and isavuconazole are all included in guideline recommendations for treatment of patients with invasive aspergillosis (IA) but the relative efficacy of isavuconazole versus AmB formulations has not been directly compared. We aimed to estimate the relative efficacy of isavuconazole compared with AmB deoxycholate (AmB-D), liposomal AmB (L-AmB), and voriconazole for the treatment of patients with proven/probable IA.
Mots clés
Amphotericin B, invasive aspergillosis, isavuconazole, network meta-analysis, voriconazole
Référence
Curr Med Res Opin. 2018 Jul 19;:1-21